UNITY Biotechnology (UBX) Stock Price, News & Analysis

Company Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.20 to $0.32
• 50-Day Range: $0.18 to $0.88
• 52-Week Range: $0.20 to $3.10
• Volume: 3.73 million shs
• Average Volume: 284,137 shs
• Market Capitalization: $3.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.33
• Consensus Rating: Hold

UNITY Biotechnology Stock Analysis - MarketRank™

UNITY Biotechnology scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

UNITY Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

UNITY Biotechnology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for UNITY Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

UNITY Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for UBX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

UNITY Biotechnology does not currently pay a dividend.

Dividend Growth

UNITY Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.60

Short Interest

There is no current short interest data available for UBX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added UNITY Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, UNITY Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.80% of the stock of UNITY Biotechnology is held by insiders.

Percentage Held by Institutions

Only 29.49% of the stock of UNITY Biotechnology is held by institutions.

UBX Stock Analysis - Frequently Asked Questions

How were UNITY Biotechnology's earnings last quarter?

UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings results on Tuesday, April, 22nd. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43).

When did UNITY Biotechnology's stock split?

Shares of UNITY Biotechnology reverse split before market open on Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did UNITY Biotechnology IPO?

UNITY Biotechnology (UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are UNITY Biotechnology's major shareholders?

UNITY Biotechnology's top institutional investors include Diadema Partners LP. Insiders that own company stock include Anirvan Ghosh, Lynne Marie Sullivan and Alexander Hieu Nguyen.
View institutional ownership trends.

What other stocks do shareholders of UNITY Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK).

Company Calendar

• Last Earnings: 4/22/2025
• Today: 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UBX
• CIK: 1463361
• Web: www.unitybiotechnology.com
• Phone: (650) 416-1192
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for UNITY Biotechnology: $2.33
• High Price Target: $4.00
• Low Price Target: $1.00
• Potential Upside/Downside: +1,203.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.99 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -246.82%
• Return on Assets: -58.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: 1.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 17,212,000
• Free Float: 16,214,000
• Market Cap: $3.08 million
• Optionable: Optionable
• Beta: 0.92